Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00057577 · ClinicalTrials.gov registry record · Phase 4
Prevention of Recurrence in Depression With Drugs and CT
A Phase 4 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 452
- Enrollment target
NCT00057577: Completed Phase 4 study, sponsored by Vanderbilt University.
NCT00057577 is a Phase 4 study that has completed, run by Vanderbilt University. The registered enrollment target is 452 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00057577, a Phase 4 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 452 participants
- Enrollment target
Study Summary
This study will determine whether the addition of Cognitive Therapy (CT) to antidepressant medication (ADM) enhances treatment for depression. This study will also test whether the addition of CT to ADM will prevent recurrences of depression after therapy is over.
Primary Outcome
Remission defined as four consecutive weeks of LIFE Problem Symptom Rating (PSR) values of 2 or less and HRSD scores of 8 or less for four consecutive weeks (with partial remission defined as LIFE PSR values of 3 or less and HRSD scores of 12 or less after month 12 only)
Interventions
- BEHAVIORAL Cognitive Therapy
- DRUG Medications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 452 participants |
| Start Date | 2002-10 |
| Est. Completion | 2014-03 |
| Phase | Phase 4 |
What the finished NCT00057577 record still lists
NCT00057577 is an interventional study that assigns participants to a tested intervention. The registered 452 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 2 interventions - of which Cognitive Therapy is the first listed.
NCT00057577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00057577 about?
NCT00057577 is a clinical study titled "Prevention of Recurrence in Depression With Drugs and CT". This study will determine whether the addition of Cognitive Therapy (CT) to antidepressant medication (ADM) enhances treatment for depression. This study will also test whether the addition of CT to ADM will prevent recurrences of depression after therapy is over.
What is the current status of trial NCT00057577?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 452 participants. The study started on 2002-10. Estimated completion is 2014-03.
What interventions are being tested in trial NCT00057577?
The interventions under investigation include: Cognitive Therapy (BEHAVIORAL), Medications (DRUG).
Who is sponsoring clinical trial NCT00057577?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00057577's enrollment target sits among peer trials
452 187th of 2000 higher than 1,814 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676255 · 452 participants · Phase 2
The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
- NCT05703178 · 452 participants · Phase 3
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
- NCT03460977 · 453 participants · Phase 1
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- NCT04708171 · 453 participants
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia